论文部分内容阅读
背景与目的:多西他赛(多西紫杉醇,进口药泰索帝,TXT)单药是晚期非小细胞肺癌二线治疗的标准治疗。本研究探讨多西他赛联合异环磷酰胺(IFO)方案与多西他赛单药治疗晚期非小细胞肺癌的疗效和不良反应。方法:随机对照研究56例非小细胞肺癌病例。共设立两组,T组:多西他赛单药方案;TI组:多西他赛联合异环磷酰胺方案。结果:PR:T组6例(23.0%);TI组7例(23.3%)。NC:T组9例(34.6%);TI组14例(46.7%)。PD:T组8例(30.8%);TI组8例(26.7%)。NE:T组3例(11.5%);TI组1例(3.3%)。两组相比,差异无显著性(P=0.6425)。1年生存率:T组21.2%;TI组22.0%。中位生存期:T组237.0 d;TI组226.0 d。两组相比,差异无显著性(P=0.8815)。中位肿瘤进展时间:T组157.1 d;TI组69.8 d。差异有显著统性(P=0.0039)。T组Ⅲ/Ⅳ度血小板减少为53.8%,TI组为16.7%,差异有非常显著性(P=0.0056)。T组Ⅲ/Ⅳ度中性粒细胞减少为65.4%,TI组为33.3%,差异有显著性(P=0.0137)。结论:多西他赛联合异环磷酰胺方案在非小细胞肺癌二线治疗中是安全、有效的,但是与多西他赛单药方案比较,有效率和生存期差异均无显著性。
Background and Objective: Docetaxel (docetaxel, imported drug taxotere, TXT) is the standard treatment for second-line treatment of advanced non-small cell lung cancer. This study was to investigate the efficacy and side effects of docetaxel plus ifosfamide (IFO) and docetaxel alone in the treatment of advanced non-small cell lung cancer. Methods: A randomized controlled study of 56 cases of non-small cell lung cancer. A total of two groups were established, T group: single docetaxel program; TI group: docetaxel combined with ifosfamide program. Results: Six patients (23.0%) in the PR: T group and seven patients (23.3%) in the TI group. NC: T group, 9 cases (34.6%); TI group, 14 cases (46.7%). PD: T group, 8 cases (30.8%); TI group, 8 cases (26.7%). NE: T group 3 cases (11.5%); TI group 1 case (3.3%). There was no significant difference between the two groups (P = 0.6425). The 1-year survival rate was 21.2% in T group and 22.0% in TI group. The median survival time was 237.0 days in T group and 226.0 days in TI group. There was no significant difference between the two groups (P = 0.8815). The median tumor progression time: T group 157.1 d; TI group 69.8 d. The difference was significant (P = 0.0039). Grade III / IV thrombocytopenia was 53.8% in the T group and 16.7% in the TI group, with a significant difference (P = 0.0056). The grade Ⅲ / Ⅳ neutropenia in group T was 65.4%, while in group TI was 33.3%, the difference was significant (P = 0.0137). CONCLUSION: Docetaxel plus ifosfamide is safe and effective in the second-line treatment of non-small cell lung cancer, but there is no significant difference in efficacy and survival between the docetaxel plus ifosfamide monotherapy regimen.